OPKO Health, Inc. (NASDAQ:OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the ...

WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the creation of a Scientific Advisory Board to provide counsel and ...

OPKO Health, Inc. (NASDAQ: OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company, in partnership with Entera Bio Ltd., announced that new data ...

Chief Executive Officer [email protected] OPKO Health Alliance Advisors IR Yvonne Briggs, 310-691-7100 [email protected] or Bruce Voss, 310-691-7100 [email protected] ...

MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3 rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025.

Miranda Toledano Chief Executive Officer [email protected] OPKO Health Alliance Advisors IR Yvonne Briggs, 310-691-7100 [email protected] or Bruce Voss, 310-691-7100 bvoss ...

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company. The company is engaged in discovering, developing, commercializing and expertise ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

Strategic Agreements: OPKO Health has been active on multiple strategic fronts. In March, the company partnered with Entera Bio to develop a once-daily oral GLP-1/glucagon dual agonist tablet ...

OPKO Health is witnessing a negative estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its loss has widened from 25 cents to 30 cents per share.

OPKO Health, Inc. (NASDAQ: OPK) has been a large holding of mine for years. There is a love/hate relationship with the stock (definitely more heavily leaning towards the hate).

Opko Health Inc. (NASDAQ:OPK) also announced a collaboration agreement with Entera Bio to advance oral GLP-1/glucagon tablet candidates into the clinic for the treatment of metabolic disorders and ...